Endothelial dysfunction in pulmonary hypertension.

Endothelial dysfunction and hypertension.

Endothelial to Mesenchymal Transition Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension.

Heterogeneity of endothelial dysfunction in hypertension.

Arginase Inhibition Reverses Endothelial Dysfunction, Pulmonary Hypertension, and Vascular Stiffness in Transgenic Sickle Cell Mice.

Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay.

Metabolic Dysfunction in Pulmonary Arterial Hypertension.

RNA Sequencing Analysis Detection of a Novel Pathway of Endothelial Dysfunction in Pulmonary Arterial Hypertension.

$Pulmonary hypertension is related to peripheral endothelial dysfunction in heart failure with preserved ejection fraction.$
Pulmonary hypertension is related to peripheral endothelial dysfunction in heart failure with preserved ejection fraction.

Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension.

Impact of pharmacologic interventions--treating endothelial dysfunction and group 2 pulmonary hypertension.

Role of microparticles in endothelial dysfunction and arterial hypertension.

Autonomic Blockade Reverses Endothelial Dysfunction in Obesity-Associated Hypertension.

Quadriceps muscle fibre dysfunction in patients with pulmonary arterial hypertension.

Pulmonary hypertension and right heart dysfunction in chronic lung disease.

Right and left heart dysfunction predict mortality in pulmonary hypertension.

Endothelial cell-specific liver kinase B1 deletion causes endothelial dysfunction and hypertension in mice in vivo.

Left ventricular dysfunction in patients with suspected pulmonary arterial hypertension.

Amphetamines promote mitochondrial dysfunction and DNA damage in pulmonary hypertension.

Kidney dysfunction in patients with pulmonary arterial hypertension.

CD51+ endothelial microparticles as a biomarker of endothelial dysfunction in obese patients with hypertension.

Treatment for pulmonary arterial hypertension-associated right ventricular dysfunction.

Are endothelial microparticles early markers of pulmonary hypertension?

Effects of bosentan on peripheral endothelial function in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.

New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication.

Suggest Documents

Endothelial dysfunction and hypertension.

Endothelial to Mesenchymal Transition Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension.

Heterogeneity of endothelial dysfunction in hypertension.

Arginase Inhibition Reverses Endothelial Dysfunction, Pulmonary Hypertension, and Vascular Stiffness in Transgenic Sickle Cell Mice.

Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay.

Metabolic Dysfunction in Pulmonary Arterial Hypertension.

RNA Sequencing Analysis Detection of a Novel Pathway of Endothelial Dysfunction in Pulmonary Arterial Hypertension.

Pulmonary hypertension is related to peripheral endothelial dysfunction in heart failure with preserved ejection fraction.

Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension.

Impact of pharmacologic interventions--treating endothelial dysfunction and group 2 pulmonary hypertension.

Role of microparticles in endothelial dysfunction and arterial hypertension.

Autonomic Blockade Reverses Endothelial Dysfunction in Obesity-Associated Hypertension.

Quadriceps muscle fibre dysfunction in patients with pulmonary arterial hypertension.

Pulmonary hypertension and right heart dysfunction in chronic lung disease.

Right and left heart dysfunction predict mortality in pulmonary hypertension.

Endothelial cell-specific liver kinase B1 deletion causes endothelial dysfunction and hypertension in mice in vivo.

Left ventricular dysfunction in patients with suspected pulmonary arterial hypertension.

Amphetamines promote mitochondrial dysfunction and DNA damage in pulmonary hypertension.

Kidney dysfunction in patients with pulmonary arterial hypertension.

CD51+ endothelial microparticles as a biomarker of endothelial dysfunction in obese patients with hypertension.

Treatment for pulmonary arterial hypertension-associated right ventricular dysfunction.

Are endothelial microparticles early markers of pulmonary hypertension?

Effects of bosentan on peripheral endothelial function in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.

New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication.

Endothelial dysfunction in pulmonary hypertension.

Recommend Documents

Follow Us